NeurologyLive® Friday 5 — January 9, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: Examining Challenges in Post-Anoxic Seizure Management: Andrea Rossetti, MD, FAES

In a recent interview, Andrea Rossetti, MD, FAES, director of the EEG/Epilepsy Unit in the Department of Clinical Neurosciences at Lausanne University Hospital in Switzerland, discussed post-anoxic seizure management at 2025 AES Annual Meeting. [WATCH TIME: 3 minutes]

2: NeurologyLive: Charting our 2026 Conference Coverage

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

3: FDA Action Update, December 2025: Acceptance, Approval, and Clearance

The FDA was busy in December 2025, making a number of decisions on potential new therapeutic agents, including accepting a new drug application, clearing the initiation of a clinical trial, granting an approval, pushing back a review, and expanding an indication.

4: NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome

In our latest NeuroVoices Q&A, a pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

5: A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines

In a recent interview, Benjamin Greenberg, MD, MHS, vice chair of clinical & translational research at UT Southwestern Medical Center, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.